The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 10, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q3 FY2022, filed Nov 10, 2022
The sections below describe the company as of the FY2021 annual report.
Sells TYRVAYA nasal spray for dry eye disease to pharmaceutical wholesalers and develops therapies for other eye diseases.
10-K for FY2021, filed Feb 24, 2022Oyster Point Pharma, Inc. (the Company) is a commercial-stage biopharmaceutical company focused on the discovery, development and…View ↗
Successfully commercialize TYRVAYA Nasal Spray, initially in the United States (U.S.) and to generate cash flows to support continued…View ↗
The Company’s customers consist of national and regional pharmaceutical wholesale distributors. The Company also uses a specialty wholesale…View ↗
A China license partner pays for rights and milestone achievements, with possible royalties tied to future product sales. U.S. wholesale distributors pay for TYRVAYA after delivery under customer-specific invoice terms.
10-K for FY2021, filed Feb 24, 2022On August 5, 2021, the Company entered into the License Agreement with Ji Xing, a biotechnology company headquartered in Shanghai, China…View ↗
Company is eligible to receive up to $204.8 million in aggregate development and sales-based milestone payments and royalty payments that…View ↗
Product Revenue and Gross to Net Deductions — Revenue from product sales is recognized upon transfer of control of a product to a customer…View ↗
The Company’s customers consist of national and regional pharmaceutical wholesale distributors. The Company also uses a specialty wholesale…View ↗
The Company's payment terms vary by type and location of customers and the products or services offered. Payment terms differ by customer…View ↗
License Revenue — The Company recognizes license revenue when the licensee has the ability to direct the use of and benefit from the…View ↗
$24.5M
10-K for FY2021, filed Feb 25, 2022
$24.5M ↗
National and regional pharmaceutical wholesalers, including a specialty wholesaler, buy TYRVAYA for U.S. distribution; the company promotes it to ophthalmologists and optometrists who prescribe it.
10-K for FY2021, filed Feb 24, 2022
10-K for FY2021, filed Feb 24, 2022
For the year ended December 31, 2021, a significant percentage of the Company's sales of TYRVAYA Nasal Spray were to large wholesale drug…View ↗
No. It lost $100.7M in FY2021.
10-K for FY2021, filed Feb 25, 2022
−$96.7MView ↗
10-K for FY2021, filed Feb 25, 2022
−$100.7MView ↗
10-K for FY2021, filed Feb 25, 2022
−$90.9MView ↗
10-Q for Q3 FY2022, filed Nov 11, 2022
−$36.7MView ↗
8-K, filed Jan 3, 2023
As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2022…View ↗
8-K, filed Nov 8, 2022
On November 7, 2022, Oyster Point Pharma, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
Competes with Aerie Pharmaceuticals, Alcon, Aldeyra Therapeutics, Abbvie, Azura Ophthalmics, Bausch Health, Glaukos, HanAll BioPharma, Johnson & Johnson, Mitotech, Novartis, Parion Sciences, ReGenTree, Silk Technologies, Sylentis, TopiVert Pharma, and TearSolutions
10-K for FY2021, filed Feb 24, 2022A number of therapies are currently available for the treatment of dry eye disease in the U.S. The most commonly used treatments for dry…View ↗
Loading...
